PE Tech Report


Like this article?

Sign up to our free newsletter

Carrick Capital Partners makes majority equity investment in Procura

Carrick Capital Partners has made a majority investment in the Procura Group of Companies, a multinational organisation specialising in healthcare software and solutions.

Procura will remain under the leadership of Scott Overhill, who has been promoted from president to chief executive officer.
Procura is a software vendor for home care, hospice, community, aged, disability and residential care organisations across the US, Canada and Australia. The organisation is comprised of Procura Home Care Solutions, Progresa Healthcare Systems, ContinuLink Homecare Software and Procura Australia (formerly PeoplePoint Solutions).
"Procura is well positioned to become a dominant player in the global home health and residential health markets," says Overhill. "We wanted a growth-oriented investment partner with a successful track record of scaling high growth companies, deep domain expertise in healthcare, and a dedication to high quality customer service. Carrick met all of our criteria. Their Approach to Building Value combined with Procura's market expertise, outstanding product depth, and dedication to customer service will help us drive increased growth and sustain our position as a market leader."
Marc McMorris, co-founder and managing director of Carrick Capital Partners, will be involved as an active member of Procura's board, and will be joined by Alex Mason, director of Carrick Capital Partners. Additionally, Michael Greenough, former CEO of SSA Global, who participated in the transaction, will take an active role as the company's executive chairman.
"As the population ages and healthcare costs continue to rise, there will be increased focus on proactively managing patient populations in the most comfortable and cost-effective settings available; patients' homes," says McMorris. "Procura has built a valuable collection of products positioned to reduce healthcare costs and improve clinical outcomes. We are excited by the opportunity to help them accelerate growth and address evolving industry pain points."

Like this article? Sign up to our free newsletter